Lipid management in type 2 diabetes

Clinical Diabetes

Volumn 24, Issue 1, 2006, Pages 27-32

  Solano, Maria P ^a   Goldberg, Ronald B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; NICOTINIC ACID; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET THERAPY; EDUCATION; GLYCEMIC CONTROL; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33244466699     PISSN: 08918929     EISSN: 08918929     Source Type: Journal    
DOI: 10.2337/diaclin.24.1.27     Document Type: Review

References (33)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala L, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
2. Smith JW, Marcus Fl, Serokman R: Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol 54:718-721, 1984
3. Miettinem H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J, for the FINMONICA Myocardial Infarction Register Study Group: Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 21:69-75, 1998
4. Demacker PN, Veerkamp MJ, Bredie SJ, Marcovina SM, de Graaf J, Stalenhoef AF: Comparison of the measurements of lipids and lipoproteins versus assay for apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia. Atherosclerosis 153:483-490, 2000
5. Cowie CC, Harris ML: Physical and metabolic characteristics of persons with diabetes. In Diabetes in America. 2nd ed. Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, Eds. Bethesda, Md., National Institutes of Health, 1995, p. 117-164
6. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR, for the U.K. Prospective Diabetes Study Group: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: UKPDS 23. BMJ 316:823-828, 1998
7. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2589, 2001
8. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; the Coordinating Committee of the National Cholesterol Education Program; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation, and Americam Heart Association: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239, 2004
9. American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care 28 (Suppl. 1):S4-S36, 2005
10. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364:685-696, 2004
11. Heart Protection Study Collaborative Group: MCR/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomized placebo-controlled trial. Lancet 361:2005-2016, 2003
12. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to prevet Heart Attack Trial (ALLHAT-LLT). JAMA 288:2998-3007, 2002
13. Sever PS, Dahlof B, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, Caufield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive subjects who have average or lower-than-average cholesterol concentratons, in the Anglo-Scandinavian Cardiac Outcome Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 361:1149-1158, 2003
14. Sever PS, Dahlof B, Poulter Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT investigators: Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes. Diabetes Care 28:1151-1157, 2005
15. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
16. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the Cholesterol and Recurrent Events (CARE) trial. Circulation 98:2513-2519, 1998
17. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelyam M, Baker J, Tonkin A: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 26:2713-2721, 2003
18. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410-418, 1999
19. Diabetes Atherosclerosis Intervention Study Investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 357:905-910, 2001
20. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 231:360-381, 1975
21. Canner PL, Furberg CD, Mc Govern ME: Niacin decreases myocardial infarction and total mortality in patients with impaired fasting glucose or glucose intolerance: results from the Coronary Drug Project [Abstract]. Circulation 106 (Suppl. 2):II-636, 2002
22. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ: Simvastatin and niacin, antioxidant vitamins, or the combination for prevent of coronary disease. N Engl J Med 345:1583-1592, 2001
23. American Diabetes Association: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (Position Statement). Diabetes Care 26 (Suppl. 1):S51-S61, 2003
24. Palumbo PJ: Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabetes Compl 12:110-119, 1998
25. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in type 2 diabetes patients and dyslipidemia. Diabetes Care 7:1547-1554, 2005
26. Pfeffer MA, Keech A, Sacks FM Cobbe SM, Tonkin A, Byington RP, Davis BR, Friedman CP, Braunwald E: Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling Project (PPP). Circulation 105:2341-2346, 2002
27. Heart Protection Study Collaborative Group: MCR/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360:7-22, 2002
28. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90:1084-1091, 2002
29. Crouse JR III: Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 83:243-248, 1987
30. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG: Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 25:1198-1202, 2002
31. Shepherd J: Fibrates and statins in the treatment of hyperlipidemia: an appraisal of their efficacy and safety. Eur Heart J 16:5-13, 1995
32. Kashyap ML, McGovern ME, Berra K, Guyton JR, Kwiterovich PO, Harper WL, Toth PD, Favrot LK, Kerzner B, Nash SD, Bays HE, Simmons PD. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 89:672-678, 2002
33. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, Baillie TA: Mechanistic studies on metabolic interactions between gemfibrozil and statins. Pharmacol Exp Ther 301:1042-1051, 2002